Abstract
New antituberculosis (anti-TB) drugs are urgently needed to battle drug-resistant Mycobacterium tuberculosis (Mtb) strains and to shorten the long treatment regimen. A series of isoxazole-based compounds, bearing a carboxy moiety at the C3 position, are highly potent and versatile anti-TB agents. Several members of this compound class exhibit submicromolar in vitro activity against replicating Mtb (R-TB) and thus comparable activity to the current first-line anti-TB drugs. Remarkably, certain compounds also show low micromolar activity in a model for nonreplicating Mtb (NRP-TB) phenotype, which is considered a key to shortening the current long treatment protocol. The series shows excellent selectivity towards Mtb and, in general, shows no cytotoxicity on Vero cells (IC50’s > 128 μM). Selected compounds retain their activity against isoniazid (INH), rifampin (RMP), and streptomycin (SM) resistant Mtb strains. The foregoing facts make derivatives of 3- isoxazolecarboxylic acid esters a promising anti-TB chemotype, and as such present attractive lead compounds for TB drug development.
Keywords: Isoxazole, Tuberculosis, mycobacterium, inhibition, drug-resistance, persistence, quinoline, micromolar activity, Vero cells, isoniazid (INH), rifampin (RMP), anti-TB chemotype, 3-isoxazolecarboxylic acid, Mefloquine
Current Topics in Medicinal Chemistry
Title:Derivatives of 3-Isoxazolecarboxylic Acid Esters - A Potent and Selective Compound Class against Replicating and Nonreplicating Mycobacterium tuberculosis
Volume: 12 Issue: 7
Author(s): Annamaria Lilienkampf, Marco Pieroni, Scott G. Franzblau, William R. Bishai and Alan P. Kozikowski
Affiliation:
Keywords: Isoxazole, Tuberculosis, mycobacterium, inhibition, drug-resistance, persistence, quinoline, micromolar activity, Vero cells, isoniazid (INH), rifampin (RMP), anti-TB chemotype, 3-isoxazolecarboxylic acid, Mefloquine
Abstract: New antituberculosis (anti-TB) drugs are urgently needed to battle drug-resistant Mycobacterium tuberculosis (Mtb) strains and to shorten the long treatment regimen. A series of isoxazole-based compounds, bearing a carboxy moiety at the C3 position, are highly potent and versatile anti-TB agents. Several members of this compound class exhibit submicromolar in vitro activity against replicating Mtb (R-TB) and thus comparable activity to the current first-line anti-TB drugs. Remarkably, certain compounds also show low micromolar activity in a model for nonreplicating Mtb (NRP-TB) phenotype, which is considered a key to shortening the current long treatment protocol. The series shows excellent selectivity towards Mtb and, in general, shows no cytotoxicity on Vero cells (IC50’s > 128 μM). Selected compounds retain their activity against isoniazid (INH), rifampin (RMP), and streptomycin (SM) resistant Mtb strains. The foregoing facts make derivatives of 3- isoxazolecarboxylic acid esters a promising anti-TB chemotype, and as such present attractive lead compounds for TB drug development.
Export Options
About this article
Cite this article as:
Lilienkampf Annamaria, Pieroni Marco, G. Franzblau Scott, R. Bishai William and P. Kozikowski Alan, Derivatives of 3-Isoxazolecarboxylic Acid Esters - A Potent and Selective Compound Class against Replicating and Nonreplicating Mycobacterium tuberculosis, Current Topics in Medicinal Chemistry 2012; 12 (7) . https://dx.doi.org/10.2174/156802612799984544
DOI https://dx.doi.org/10.2174/156802612799984544 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Drug-Induced Liver Injury: Mechanisms, Types and Biomarkers
Current Medicinal Chemistry γ δ T Cells and Dendritic Cells: Close Partners and Biological Adjuvants for New Therapies
Current Molecular Medicine Immunomodulatory Activity of Garlic
Current Immunology Reviews (Discontinued) Tuberculosis Deaths Among Populations with High HIV Prevalence
Current Respiratory Medicine Reviews Vaccine Delivery - Current Trends and Future
Current Drug Delivery Hydrogel-clay Nanocomposites as Carriers for Controlled Release
Current Medicinal Chemistry Patent Selections
Recent Patents on Inflammation & Allergy Drug Discovery Synthesis, Screening and Docking Analysis of Hispolon Pyrazoles and Isoxazoles as Potential Antitubercular Agents
Current Topics in Medicinal Chemistry Development and Implementation of the DHAPP Military eHealth Information Network System
Current HIV Research Molecular Dynamics Simulations of Protein Targets Identified in Mycobacterium tuberculosis
Current Medicinal Chemistry Central Nervous System Vasculitis: Still More Questions than Answers
Current Neuropharmacology Integrating the Universe of Effector and Regulatory Immune Cell Subsets: An Emerging Role of Protein-Glycan Interactions
Current Immunology Reviews (Discontinued) Targeted Drug Delivery in Brain Tumors-nanochemistry Applications and Advances
Current Topics in Medicinal Chemistry New Insights into the Immune Response to Pneumococci
Current Respiratory Medicine Reviews From new Diagnostic Targets to Recombinant Proteins and Semi-Synthetic Protein-Based Vaccines
Current Organic Chemistry Nanoemulsion for the Effective Treatment and Management of Anti-tubercular Drug Therapy
Recent Patents on Anti-Infective Drug Discovery Therapeutic Outlook of Pyrazole Analogs: A Mini Review
Mini-Reviews in Medicinal Chemistry Prospects of Bacteriotherapy with Nanotechnology in Nanoparticledrug Conjugation Approach for Cancer Therapy
Current Medicinal Chemistry Nanoformulations of Moxifloxacin, Econozole and Ethionamide as Novel Treatment Regimens Against MDR TB - An Experimental Study
Current Nanoscience Fcγ Receptor 1 (CD64), a Target Beyond Cancer
Current Pharmaceutical Design